CareDx, Inc
NASDAQ:CDNAMedical - Diagnostics & Research
+$1.19 today
- Market cap
- $3.91B
- Beta
- 2.48
- P/E (TTM)
- -154.0
- EPS (TTM)
- -$0.16
Volume 0.54M
Average 0.74M
CDNA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
CareDx, IncNASDAQ: CDNA
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development growth accelerates
Q2 FY2026 research & development of $22.38M rose 33.0% year over year, ahead of the +15.1% change in trailing-twelve-month research & development. Sequentially, it rose 4.5% from the prior quarter. Over 3 fiscal years it compounded at -7.5% a year.
Context
- Research & development amounted to 18.8% of revenue in FY2025, down 2.9 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +33.0% holds above the trailing-twelve-month pace of +15.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 71.43M USD
- Year-over-year change
- -1.3%
- 4-year CAGR
- -1.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 71.43M | -1.3% |
| FY2024 | 2024-12-31 | 72.41M | -11.6% |
| FY2023 | 2023-12-31 | 81.87M | -9.4% |
| FY2022 | 2022-12-31 | 90.39M | +18.1% |
| FY2021 | 2021-12-31 | 76.53M | — |
Research & Development vs competitors
How CDNA compares with its peers on the latest reported figures
- CDNA's LTM Jun 2026 research & development of $79.87M is the 6th highest of the 8 companies compared; the peer median is $93.37M.
- Its year-over-year change of +15.1% is the 5th highest of 8, against a peer median of +31.8%.
- Research & development amounts to 17.4% of revenue for CDNA, versus a peer median of 16.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $787.38M | +56.9% | +25.4% | 29.1% | |
| LTM Jun 2026 | $194.67M | +5.5% | -0.4% | 9.3% | |
| LTM Mar 2026 | $106.4M | -7.7% | +7.7% | 12.8% | |
| LTM Jun 2026 | $93.37M | +31.8% | +20.4% | 16.6% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $83.32M | +64.3% | -5.8% | 18.3% |
| LTM Jun 2026 | $79.87M | +15.1% | -7.5% | 17.4% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $59.21M | +38.6% | — | 14.9% |
| LTM Mar 2026 | $55.69M | +11.9% | +23.1% | 17.4% | |
| Peer median (excluding CDNA) | $93.37M | +31.8% | +14.1% | 16.6% | |
Competitors are the stored peer set for CDNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 296.4M | 321.79M | 280.32M | 333.79M | 379.81M |
| Cost of Revenue | 97.39M | 112.21M | 102M | 109.63M | 123.24M |
| Gross Profit | 199.01M | 209.58M | 178.33M | 224.16M | 256.57M |
| Gross Margin | 67.1% | 65.1% | 63.6% | 67.2% | 67.6% |
| Research & Development | 76.53M | 90.39M | 81.87M | 72.41M | 71.43M |
| Selling, General & Admin | 152.21M | 196.42M | 201.2M | 205.5M | 210.21M |
| Operating Expenses | 228.73M | 286.81M | 381.69M | 183.39M | 281.64M |
| Depreciation & Amortization | 11.89M | 16.01M | 19.82M | 19.76M | 20.42M |
| EBITDA | (20.2M) | (60.23M) | (84.92M) | (34M) | (4.66M) |
| EBITDA Margin | -6.8% | -18.7% | -30.3% | -10.2% | -1.2% |
| Operating Income | (29.73M) | (77.23M) | (203.36M) | 40.77M | (25.07M) |
| Operating Margin | -10.0% | -24.0% | -72.5% | 12.2% | -6.6% |
| Interest Income | 160K | 3.76M | 11.87M | 11.77M | 9.17M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (2.36M) | 997K | 13.22M | 12.09M | 3.99M |
| Income Before Tax | (32.09M) | (76.23M) | (190.14M) | 52.86M | (21.08M) |
| Pre-Tax Margin | -10.8% | -23.7% | -67.8% | 15.8% | -5.6% |
| Income Tax Expense | (1.43M) | 379K | 141K | 310K | 271K |
| Net Income | (30.66M) | (76.61M) | (190.28M) | 52.55M | (21.35M) |
| Net Margin | -10.3% | -23.8% | -67.9% | 15.7% | -5.6% |
| EPS (Basic) | (0.59) | (1.44) | (3.54) | 1.00 | (0.40) |
| EPS (Diluted) | (0.59) | (1.44) | (3.54) | 0.93 | (0.40) |
| Weighted Avg Shares | 52.24M | 53.32M | 53.76M | 52.77M | 53.29M |
| Weighted Avg Shares (Diluted) | 52.24M | 53.32M | 53.76M | 56.62M | 53.29M |
CareDx, Inc
NASDAQ:CDNA
Intrinsic Alpha fair value
Locked
Current Price
$74.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.